C4XD signs NRF2 Activator deal with AstraZeneca
C4XD will receive milestone payments worth up to $16m ahead of the first clinical trial
Read More
Tag: NRF2
- Arvinas reports strong phase 1 results for ARV-102 in Parkinson’s disease
- Alzecure shares new preclinical data on NeuroRestore ACD856 at AD/PD conference
- Samsung Bioepis signs partnership with Sandoz for next‑generation biosimilars
- Atrogi begins dosing first subjects in human trial of ATR-258
- R1 Therapeutics launches with $77.5m to advance hyperphosphatemia treatment
